Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  PCAS    PCA   FR0000053514

PCAS (PCA)

Delayed Quote. Delayed  - 12/09 10:26:07 am
12.29 EUR   +1.99%
11/22 PCAS : Acquisition of a leading R&D Center
11/22 PCAS : Acquisition of a leading r&d center
11/04 PCAS : at China INTER LUBRIC 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

PCAS : Quarterly Financial Information as of March 31st 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/23/2012 | 05:40pm CET

PCAS: Quarterly Financial Information As of March 31st, 2012

 
 
 
 

Longjumeau, April 23rd,  2012

Business update

(in million of euros) 2012 2011 % change
Sales as of 31 March 42 728 44 053 -3,0%
including Pharmaceutical Synthesis 25 454 27 147 -6,2%
including Specialty Chemicals 17 274 16 906 2,2%

Consolidated revenue for PCAS as of 31 March is down 3% in 2012 compared with 2011.

Pharma Synthesis
Business was affected by the planned reduction in contribution from the new contract between PCAS and Sanofi.  However, it is still more robust than the drop in revenue would suggest, thanks to the manufacture of two products with long production cycles, sales of which will be effective through the second quarter of 2012.

Fine & Speciality Chemicals
Fine & Speciality Chemicals rose slightly by 2.2% in 2012, thanks to the activities of New Technologies whereas, Performance Chemicals and Fragrance-Flavour-Cosmetics are down slightly over the period.

However, these data should not hide the fact that 2012 revenue is still set to be considerably higher than that of 2011.

Confirmation of the Group's development strategy focused on the increase of the percentage of proprietary products and the development of differentiating technologies, coupled with continued rigorous management of all costs, is resulting as from the first quarter of 2012 in significantly higher profitability.

Key operations and events for the quarter

No important events likely to have a significant impact on the company's business or situation occurred during the first quarter of 2012.

Outlook for the current year

As requested by the Board of Directors, the Group's General Management is focusing its action on ensuring sustained improvement in profitability.

Next meeting:
2012 first half sales, on 26 July 2012

 

 

 

 

 

 
 

Founded in 1962, PCAS is a fine and specialty chemicals group that shares an ambition for excellence with its customers, which primarily include market-leading international groups. PCAS designs and delivers the best industrial solutions for its customers' specific expectations. These various expectations all share a common demand for safety, quality, competitiveness, innovation and sustainability.

 
 
 
PCAS_CAQ1:
http://hugin.info/143512/R/1605084/508120.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PCAS via Thomson Reuters ONE

HUG#1605084
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PCAS
11/22 PCAS : Acquisition of a leading R&D Center
11/22 PCAS : Acquisition of a leading r&d center
11/04 PCAS : at China INTER LUBRIC 2016
11/03 PCAS : net sales as of 30 September, 2016
09/14 PCAS : ex-dividend day for interim dividend
09/07 PCAS : 1st half 2016 earnings report continued organic growth
09/02PCAS : half-yearly earnings release
07/19 PCAS : Net sales for the 1st half of 2016
07/19 PCAS : SUSTAINED GROWTH IN NET SALES FOR THE 1st HALF OF 2016
07/13 PCAS : signs a global distribution agreement with MilliporeSigma
More news
Sector news : Pharmaceuticals - NEC
12/08 BRISTOL MYERS SQUIBB : Meyers Squibb to pay $19.5 million to settle off-label pr..
12/07 MYLAN : EpiPen maker Mylan to restructure, cut workforce
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal -- Update
12/07DJPFIZER : Fined $107 Million for Overcharging U.K. for Epilepsy Drug
12/07DJABBOTT LABORATORIES : Seeks to Terminate Alere Deal
More sector news : Pharmaceuticals - NEC
Advertisement
Financials (€)
Sales 2016 194 M
EBIT 2016 17,0 M
Net income 2016 9,70 M
Debt 2016 33,6 M
Yield 2016 1,55%
P/E ratio 2016 16,97
P/E ratio 2017 13,96
EV / Sales 2016 1,11x
EV / Sales 2017 1,04x
Capitalization 182 M
More Financials
Chart PCAS
Duration : Period :
PCAS Technical Analysis Chart | PCA | FR0000053514 | 4-Traders
Full-screen chart
Technical analysis trends PCAS
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 3
Average target price 13,3 €
Spread / Average Target 10%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Vincent Touraille CEO & Financial Communications Contact
Christian Moretti Chairman
Pierre Schreiner Deputy Chief Executive Officer-Operations
Eric Moissenot Deputy CEO-Finance & Administration
Gérard Guillamot Director-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PCAS46.80%194
JOHNSON & JOHNSON8.05%301 952
ROCHE HOLDING LTD.-19.97%189 184
PFIZER INC.-3.38%187 755
NOVARTIS AG-20.79%178 671
MERCK & CO., INC.13.82%165 759
More Results